Alivia established the IMAB to bring you the expertise of internationally renowned physicians who are leaders in their respective disciplines. The resources of the Medical Intelligence Unit , coupled with cross border relationships and networks of the IMAB members, provide you with unprecedented access to the latest medical intelligence, leading experts and premier treatment facilities. Additionally, IMAB members participate on multi-disciplinary expert panels coordinated by Alivia in connection serious medical conditions of Cure clients.
He was a founding member of the Academy of Medical Sciences. He is distinguished for biomarker research Notably apolipoprotein B as one of the most powerful cardiovascular disease risk predictors and for the discovery of the totally novel mechanism of nucleic acid editing, a process concerned with cholesterol transport, antibody formation, protection against HIV and stem cell programming.
Professor Scott has discovered common genetic variation causing dyslipidaemia, heart disease and obesity. Current interests concern genetic and epigenetic mechanisms and systems biology studies in cardiovascular and metabolic disease, and preventive medicine. Professor Ben-Menachem is a member of numerous international medical journals and is a world-renowned expert as well as a frequent speaker at medical conferences around the world.
He played a key role in the formation of the Cardiovascular Institute at The Mount Sinai Medical Center, one of the leading centers for integrated cardiovascular research, education and patient care in the United States, and has served as its associate director since its inception. He was also instrumental in the evolution of the Joseph H. Hazen Cardiology Clinics as a model of ambulatory care, preventive medicine and professional education, and Mount Sinai Heart, which integrates and unifies in-patient cardiovascular services.
He trained at Trinity College Oxford, where he gained a triple first class degree. His focus at Imperial is on new therapies in cancer and the systemic management of patients with solid malignancies including a number of new biomarker-based approaches, with an emphasis on circulating tumor cells. His laboratory work is concentrated on new druggable target discovery. He is a Fellow of the Royal College of Physicians, the American Board of Internal Medicine and the Royal College of Pathologists, and sits on the advisory boards of a number of international cancer committees.
